GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intec Parent Inc (NAS:NTEC) » Definitions » Total Liabilities

Intec Parent (Intec Parent) Total Liabilities : $6.09 Mil (As of Mar. 2021)


View and export this data going back to 1996. Start your Free Trial

What is Intec Parent Total Liabilities?

Intec Parent's Total Liabilities for the quarter that ended in Mar. 2021 was $6.09 Mil.

Intec Parent's quarterly Total Liabilities increased from Sep. 2020 ($5.96 Mil) to Dec. 2020 ($6.36 Mil) but then declined from Dec. 2020 ($6.36 Mil) to Mar. 2021 ($6.09 Mil).

Intec Parent's annual Total Liabilities increased from Dec. 2018 ($7.97 Mil) to Dec. 2019 ($9.75 Mil) but then declined from Dec. 2019 ($9.75 Mil) to Dec. 2020 ($6.36 Mil).


Intec Parent Total Liabilities Historical Data

The historical data trend for Intec Parent's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent Total Liabilities Chart

Intec Parent Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Total Liabilities
Get a 7-Day Free Trial 2.02 5.75 7.97 9.75 6.36

Intec Parent Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.42 5.61 5.96 6.36 6.09

Intec Parent Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Intec Parent's Total Liabilities for the fiscal year that ended in Dec. 2020 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.334+(0.338+0.691
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=6.36

Total Liabilities=Total Assets (A: Dec. 2020 )-Total Equity (A: Dec. 2020 )
=20.896-14.533
=6.36

Intec Parent's Total Liabilities for the quarter that ended in Mar. 2021 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.203+(0.178+0.705
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=6.09

Total Liabilities=Total Assets (Q: Mar. 2021 )-Total Equity (Q: Mar. 2021 )
=17.43-11.344
=6.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intec Parent Total Liabilities Related Terms

Thank you for viewing the detailed overview of Intec Parent's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Parent (Intec Parent) Business Description

Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.
Executives
Walt Addison Linscott officer: Chief Business Officer 1860 MONTREAL ROAD, TUCKER GA 30084
Nir Sassi officer: Chief Financial Officer 3 ELUL STREET, APT. 6, MODIIN L3 7176397
Nadav Navon officer: Chief Operating Officer 18 LEA IMENU STREET MODIIN L3 7177945
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes director 231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Jeffrey A Meckler director, officer: Chief Executive Officer 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
R Michael Gendreau officer: Chief Medical Officer 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Gil Bianco director 7 HAORANIM STREET BAZRA L3 60944